Herke specializes in venture capital, private equity, mergers & acquisitions, joint ventures and advises clients on corporate governance and other corporate law issues.

Herke has a broad transactional and corporate advisory practice. She has extensive experience in transactions in Healthcare & Life Sciences and TMC. Clients include national and international private equity and venture capital firms, investment funds and national and international corporate clients.

Herke is a graduate of the University of Utrecht, studied law at Panthéon-Assas in Paris, and was admitted to the Dutch bar in 1996. Prior to joining Osborne Clarke in December 2015, Herke was Counsel at Clifford Chance LLP in Amsterdam where she worked for 15 years.

Over the course of her career Herke worked from Amsterdam, London and Kuala Lumpur.

Legal 500 mentions Herke as a ‘Highly talented, pragmatic’ Healthcare & Life Sciences expert and reported her as 'skilled, supportive'.

Herke is recognised by Client Choice in 2019 for her excellence in client service.

Herke has registered the following principal (and secondary) legal practice areas in the Netherlands Bar’s register of legal practice areas (rechtsgebiedenregister):
- Corporate Law
- Companies
- Associations and Foundations
- Mergers and Acquisitions
- Director's liability

Based on this registration, she is required to obtain ten training credits per calendar year in each registered principal legal practice area in accordance with the standards set by the Netherlands Bar.

Work

MILabs

Advised the shareholders of MILabs on the sale of the company’s entire issued share capital to Rigaku Corporation, read more.

DSM Venturing

Advised DSM Venturing on the $47 million Series A funding round in innovative food company, Meatable. Read more >

VarmX

Advised the syndicate of investors on VarmX’s EUR 32 million Series B financing round financing, read more.

Oaky

Advised Oaky on $9.5M Series A financing by PeakSpan Capital, read more.

Isobionics

Advised on the sale of Isobionics to BASF, read more.

Breath Therapeutics

Advised on the sale of Breath Therapeutics to Zambon. 

Infosys

Advised Infosys on a strategic partnership with ABN AMRO, including the acquisition of a majority-stake in Stater.

EQT Ventures

Advised EQT Ventures on a co-lead €20m funding round for Amsterdam-based electric scooter company Dott

Lava Therapeutics

Advised a syndicate of investors led by Gilde Healthcare and Versant Ventures with additional support from US-based MRL Ventures Fund in the EUR 16 million financing round of Lava Therapeutics, read more

NightBalance

Represented the founders, INKEF Capital, Gilde Healthcare, Thuja Capital Healthcare, Health Innovation Fund, Van Herk Ventures (sellers) in the sale of NightBalance to Royal Philips. Nightbalance is a digital health scale-up company based in the Netherlands, that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. Read more

Bioclin Therapeutics

Represented new investors INKEF Capital and Sectoral Asset Management as well as existing investors Sofinnova Ventures and Ysios Capital in respect of the USD 50 million Series B financing round of BioClin Therapeutics. Other investors include HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP). Read more

EQT Ventures

Advised EQT Ventures with the investment in Siilo, a secure mobile messaging service bringing medical teams together.

HH Global

Advised HH Global, an award winning leading independent marketing execution partner to global brands in over 40 countries employing over 850 employees, with its acquisition of PostNL Print Management, the print management arm of the Dutch postal and logistic solutions provider PostNL, to help support HH Global’s growth in the Netherlands.

ViroClinics

Represented Gilde Healthcare and key management (sellers) in the auction sale of ViroClinics Biosciences B.V. to Parcom Capital, a leading mid-market private equity firm in the Benelux, as well key management in their continuing investment in ViroClinics post-closing.

A-Gas

Advised A-Gas on the acquisition of Netherlands' reclamation business BTC.

Terumo Corporation

Represented Terumo Corporation in respect of the staged transaction with Quirem Medical, in which Terumo Corporation following its initial minority interest (i)  increased its minority interest, (ii) acquired  the exclusive worldwide distribution rights and (iii) obtained a purchase option to acquire the remaining of the shares.

Breath Therapeutics

Represented Breath Therapeutics on EUR 43.5m Series A financing round by Gimv, Sofinnova Partners and Gilde Healthcare.

Sofinnova Ventures & Ysios Capital

Represented Sofinnova Ventures and Ysios Capital as lead investors in the USD 30 million Series B Financing round of BioClin Therapeutics.

Northsea Therapeutics

Advised lead investors Ysios Capital and Forbion Growth on Northsea Therapeutics' USD 80 million Series C financing round.

GenDx

Osborne Clarke  has advised the shareholders of Genome Diagnostics B.V. (GenDx) in the competitive auction process relating to the sale of GenDx to Eurobio Scientific for an amount of €135 million

Mayht Holding B.V.

Osborne Clarke assisted Mayht and its shareholders on the acquisition by Sonos.